Reply  by Benito, Begoña et al.
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Erugada Syndrome or
rugada Electrocardiogram?
e read with great interest the paper by Benito et al. (1) from the
rugada group. The authors confirm that important differences
xist between men and women regarding the clinical picture and
utcome in patients with Brugada syndrome. In general, in men
he clinical picture appears more severe and the outcome is worse.
lthough this may seem presumptuous, we wonder if all subjects
n this study truly had Brugada syndrome, in particular the women.
rom the paper, it reads as if the diagnosis “Brugada syndrome” is
ynonymous with the presence of a type-1 electrocardiogram
ECG) (coved-type, either spontaneously or after pharmacologic
rovocation with a sodium-channel blocker). It is not mentioned
hether additional clinical features were required for the diagnosis.
ccording to the consensus statement (2), in addition to a
Brugada ECG” (type-1 ECG), for Brugada syndrome to be
efinitely diagnosed at least 1 of the following clinical features is
equired: documented ventricular fibrillation or polymorphic ven-
ricular tachycardia, a family history of sudden death at 45 years
f age, coved-type ECGs in family members, inducibility of
entricular tachycardia with programmed electrical stimulation,
yncope, or nocturnal agonal respiration. In other words, a Bru-
ada ECG is not sufficient to diagnose Brugada syndrome, and
his is a very important point both in clinical practice and in
cientific studies. When applying the above criteria to the study by
enito et al. (1), some uncertainty remains. According to Table 2
n their paper (1), in women syncope was present “only” in 15%,
borted sudden cardiac death in 1%, a history of sudden cardiac
eath in 45%, and programmed electrical stimulation was per-
ormed in 81% with inducibility in 12%. If anything, these figures
o not add up to 100%. Of note, there was also a difference in the
aseline ECG; as many as 62% of the women had a normal or
ype-3 ECG as opposed to only 25% of the men. Obviously, in
ubjects in whom the diagnosis of Brugada syndrome is not firmly
stablished, a mild clinical picture and a good outcome can be
xpected.
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eply
e thank Dr. van den Berg and colleagues for their interest in our
rticle (1) and their valuable comments, which raise important
ssues regarding the diagnosis of Brugada syndrome. Indeed, a
yndrome requires a constellation of symptoms and signs for
iagnosis, and a single electrocardiographic finding does not define
syndrome. Dr. van den Berg and colleagues do certainly realize
hat Brugada syndrome is no longer a syndrome but a disease.
fter the description of the first mutation in the sodium channel
ausing Brugada syndrome (2), a multitude of other mutations in
he sodium and other channels have been described. It is clear that
he consensus report from 2005 (3) is more than outdated and an
pdate is urgently required in terms of both diagnosis and
herapeutic approach.
The definite phenotypic manifestation of the Brugada syndrome
s the presence of a type-1 electrocardiogram (ECG), either
pontaneously or after sodium-blocker challenge. Given that even
he sole presence of the ECG pattern has been proven to entail a
isk of sudden cardiac death, this was the only prerequisite required
n all of our 384 patients included in the study, as stated in the
rticle (1). However, in reply to Dr. van den Berg and colleagues,
e must say that most of our patients, both men and women and
n similar proportions (82.4% vs. 89.3%, respectively, p  0.06),
id fulfill the II Consensus Report definition of Brugada syn-
rome. Therefore, the better prognosis in women cannot be
xplained because of their lower rate of “confirmed diagnosis”
ccording to the consensus. As can be drawn from our article, in
ddition to the type-1 ECG, 66 of the 272 male patients (24.3%)
lso had symptoms, 82 (30.1%) had a family history of early
udden death, and 84 (31.9%) had documented ventricular fibril-
ation either spontaneous or inducible at the time of diagnosis.
ecause these clinical variables tended to meet within the same
ndividual, they resulted in a total of 148 (54.4%) patients.
dditionally, in 74 (27.2%) more men, a type-1 ECG was
ocumented in at least 1 family member. Therefore, at the time of
heir first evaluation, 222 of 272 patients (81.7%) had a confirmed
iagnosis of Brugada syndrome according to the II Consensus
efinition. On the other hand, a total of 100 of 112 female patients
89.3%) fulfilled the Consensus criteria of Brugada syndrome (62
55.4%] because of symptoms, family history of sudden death,
ocumented ventricular fibrillation, or a combination, and 38
33.9%] because of none of the others and a presence of type-1
CG in family members). Importantly, among the 62 patients (50
en and 12 women) who did not meet the II Consensus definition
o
e
w
l
p
c
t
E
B
*
R
P
*
A
U
V
0
S
E
R
1
2
3
L
A
A
T
W
l
i
m
s
e
L
o
u
fi
(
r
L
2
T
a
m
r
m
r
o
w
a
f
r
u
t
c
T
m
m
d
d
t
a
r
fi
m
s
o
m
u
i
a
e
A
d
i
t
L
t
f
*
S
S
*
P
U
V
9
I
E
R
1
1570 Correspondence JACC Vol. 53, No. 17, 2009
April 28, 2009:1569–72f Brugada syndrome at the time of first evaluation, 2 men
xperienced sudden death in follow-up, increasing the total of men
ith “confirmed diagnosis” to 224 (82.4%). The occurrence of
ife-threatening events in patients not fulfilling the clinical criteria
roposed by the consensus attests to the need to interpret with
aution the definition of Brugada syndrome, and also reminds us of
he importance of following up all patients even when a type-1
CG pattern is found in isolation.
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eft Dominant
rrhythmogenic Cardiomyopathy
New Clinical Entity Without a
ypical Substrate of Myocardial Damage
e read with interest the paper by Sen-Chowdhry et al. (1) about
eft dominant arrhythmogenic cardiomyopathy (LDAC). The
nvestigators “highlight the interrelation of LDAC and arrhyth-
ogenic right ventricular cardiomyopathy (ARVC) within the
ame disease spectrum and provide a composite profile of this
ntity” (1). The investigators identify the salient clinical features of
DAC: unexplained ventricular arrhythmia of left ventricular
rigin, isolated (infero)lateral T-wave inversion, mild left ventric-
lar dilation and/or systolic impairment, and myocyte loss with
brofatty or fibrotic replacement. Additionally, the involvement
segmental dilatation and/or wall motion abnormalities) of the
ight ventricle (RV) showed an important role in the diagnosis of
DAC.
On the basis of myocardial damage, the investigators illustrated
phenotypes of LDAC: a fibrofatty and a pure fibrotic form.
herefore, the identification of myocardial damage by histology
nd/or cardiac magnetic resonance with late gadolinium enhance-ent added with clinical manifestation of this disease plays a main
ole in the diagnosis of LDAC.
However, LDAC shows controversial points, particularly in its
orphological features. We believe that LDAC is an under-
ecognized entity because it has many morphological features
verlapping with those of other cardiomyopathies, particularly
ith dilated cardiomyopathy (DCM), biventricular form ARVC,
nd inflammatory cardiomyopathy (myocarditis).
The investigators suggest differentiating the LDAC phenotype
rom DCM on the basis of prominent RV abnormalities; however,
ecognizing “prominent RV abnormalities added with left ventric-
lar involvement” as a diagnostic method for LDAC with respect
o the biventricular form of ARVC can be very difficult.
Furthermore, the investigators suggest the localization of myo-
ardial damage (fibrofatty or fibrotic tissue) as an aid to diagnosis.
o distinguish these 2 entities (LDAC and DCM), they recom-
end the epicardial pattern of damage (late gadolinium enhance-
ent) as indicating a suspicion of LDAC, whereas midventricular
amage can be observed in both. Nevertheless, the epicardial
amage is an unspecific pattern observed in many cardiomyopa-
hies, such as myocarditis, sarcoidosis, Anderson-Fabry disease,
nd Chagas disease.
According to the investigators, fibrofatty replacement likely
epresents a nonspecific reparative process. This theory is con-
rmed by lipomatous metaplasia observed in the context of a
yocardial infarction; the lipomatous metaplasia is caused by
ubstitution of muscle fibers with fibrofatty tissue (2).
Recent studies suggest that the LDAC phenotype is the result
f chronic myocarditis (3). However, the investigators attribute the
yocardial inflammation in the setting of LDAC to a reactive
nspecific consequence of loss of myocyte caused by compromised
ntercellular adhesion and intermediate filament function attribut-
ble to mutation in desmosomal genes. On the contrary, Bowles
t al. (4) have identified the viral genome in the myocardium of
RVC; therefore, it is also possible that a genetic profile of
iseased myocardium has increased the susceptibility to a viral
nfection that can eventually play a role in the clinical manifesta-
ions of the disease (5). Therefore, the role of inflammation in
DAC pathogenesis remains unknown.
Finally, we concur with the view of Sen-Chowdhry et al. (1)
hat the results described in their article add important clinical
eatures to facilitate the diagnosis of LDAC.
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